- The Lancet - All Issues
The Lancet Gastroenterology Hepatology; The Lancet Global Health; The Lancet Haematology; The Lancet Healthy Longevity; The Lancet HIV; The Lancet Infectious Diseases; The Lancet Microbe; The Lancet Neurology; The Lancet Obstetrics, Gynaecology, Women's Health; The Lancet Oncology; The Lancet Planetary Health; The Lancet Primary Care; The
- Our journals - The Lancet
Lancet journals are internationally trusted sources of clinical, public health, and global health knowledge covering a broad range of clinical and global health specialties; essential early evidence through The Lancet Discovery Science; and all six regions of the world with The Lancet Regional Health
- The Lancet Digital Health
Fast-track peer-review: The Lancet Digital Health offers a fast-track process for research articles, where papers can be published online within 4–8 weeks Submit your paper Information for authors : Find out how to format your research paper and related materials for submission to The Lancet Digital Health
- Assessing worldwide trends of underweight and obesity - The Lancet
The NCD Risk Factor Collaboration (NCD-RisC)1 presents an international study that observed an increase in obesity prevalence between 1990 and 2022 1 Based on their findings the authors emphasise that there is an urgent need for obesity prevention, supporting weight loss, and reducing disease risk in those with obesity A limitation, only partly acknowledged by the authors, is the use of BMI
- Introducing The Lancet Obstetrics, Gynaecology, Women’s Health
The Lancet Obstetrics, Gynaecology, Women’s Health will showcase original research, evidence-based reviews, and insightful features on women’s health, obstetrics, and gynaecology, encompassing the entire life course—from adolescence through menopause and beyond
- COVID-19 Resource Centre - The Lancet
As of January 2024, changes have been made to our COVID-19 Resource Centre A COVID-19 Collection is available where you can continue to explore and access The Lancet Group's COVID-19 research, reviews, commentary, news, and analysis as it is published
- Semaglutide and walking capacity in people with . . . - The Lancet
Semaglutide increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes Research implications include the need for future studies to further elucidate mechanisms of benefit and to assess the efficacy and safety in patients with peripheral artery disease who do not have type 2 diabetes
- eClinicalMedicine Home Page - The Lancet
eClinicalMedicine, together with eBioMedicine, is part of The Lancet Discovery Science — a suite of open access journals that span basic, translational, clinical, and health systems research They publish essential, early evidence that helps researchers and clinicians alike to identify new opportunities with the potential to improve the health and wellbeing of people around the world
|